// App-Quantinova.ai

AB0422 : SELECTIVE FACTOR XA INHIBITORS IN TREATMENT AND PREVENTION OF THROMBOSES IN PATIENTS WITH RHEUMATIC DISEASES

Researchers

Presenter

  • N. Seredavkina

Principal Investigators

  • T. Reshetnyak

  • M. Satybaldyeva

  • L. Kashnikova

  • E. Nasonov

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

  • Anti-neutrophil cytoplasmic antibody-associated vasculitis

  • Antiphospholipid syndrome

  • Pulmonary arterial hypertension

  • Venous thrombosis

  • Deep vein thrombosis

  • Rheumatoid arthritis

  • Scleroderma

  • Behcet disease

  • Thrombocytopenia

  • Osteoarthritis

  • Hypertension

  • Inflammatory Arthritis

  • Nephritis

Biomarkers

  • B-cell activating factor

Drug/Treatment

  • Fondaparinux sodium

  • rivaroxaban

  • Enoxaparin

  • Enoxaparin sodium

  • Fibrinogen (IV)

  • nadroparin

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved